Companion Diagnostics
News on companion diagnostics and drug/test co-development.
FDA Approves Bile Duct Cancer Drug from Helsinn, BridgeBio Pharma With Foundation Medicine CDx
Truseltiq is a new option for FGFR2 fusion-positive, locally advanced, or metastatic cholangiocarcinoma patients who have received prior treatment.
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
Qiagen, Mirati Therapeutics Partner to Develop KRAS Companion Test for NSCLC Drug
The tissue-based test will identify cancer patients who may benefit from adagrasib, Mirati's investigational oral small molecule inhibitor of KRAS G12C.
LGC SeraCare Joins Diaceutics DXRX Network for Precision Medicine Diagnostics
The partnership will introduce additional types of test reference materials to users of the platform, including the Seraseq FFPE Tumor Fusion RNA Reference Material v4.
Burning Rock Biotech, Abbisko Therapeutics Ink CDx Partnership for ABSK091
Burning Rock will use its sequencing platform to identify urothelial carcinoma patients with FGFR alterations, supporting development of Abbisko's drug.